[双膦酸盐在骨质疏松性骨折一级和二级预防中的地位:肠外治疗的作用——修改治疗标准的建议]。

Jarosław Deszczyński, Tomasz Rawo, Tomasz Petelewicz
{"title":"[双膦酸盐在骨质疏松性骨折一级和二级预防中的地位:肠外治疗的作用——修改治疗标准的建议]。","authors":"Jarosław Deszczyński,&nbsp;Tomasz Rawo,&nbsp;Tomasz Petelewicz","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Oral bisphosphonates are currently known as medicines of a first choice in the treatment of osteoporosis and in preventing age-related fractures. However, despite their advantages, these medicines are not free of limitations. The most significant one is a complicated way of tablet administration, requiring from patients to remain upright position and to take a tablet before a meal. This may make the administration of other, chronic medicines, such as thyroid hormones, more difficult. Complications of the therapy include dyspepsia and gastrointestinal disorders. Approximately 48% of individuals taking bisphosphonates once a week resign from therapy within one year from the beginning of the treatment. There is a group of individuals who cannot take bisphosphonates orally at all. The alternative here is an intravenous injection. Therefore, there is a need for modifications of the existing therapeutic standards for osteoporosis. It is also necessary to emphasise the significance of intravenous medicines in the treatment of this disease.</p>","PeriodicalId":75702,"journal":{"name":"Chirurgia narzadow ruchu i ortopedia polska","volume":"76 4","pages":"225-31"},"PeriodicalIF":0.0000,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Place of bisphosphonates in the primary andsecondary prophylaxis of osteoporotic fractures: the role of parenteral therapy--proposal to modify the standards of treatment].\",\"authors\":\"Jarosław Deszczyński,&nbsp;Tomasz Rawo,&nbsp;Tomasz Petelewicz\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oral bisphosphonates are currently known as medicines of a first choice in the treatment of osteoporosis and in preventing age-related fractures. However, despite their advantages, these medicines are not free of limitations. The most significant one is a complicated way of tablet administration, requiring from patients to remain upright position and to take a tablet before a meal. This may make the administration of other, chronic medicines, such as thyroid hormones, more difficult. Complications of the therapy include dyspepsia and gastrointestinal disorders. Approximately 48% of individuals taking bisphosphonates once a week resign from therapy within one year from the beginning of the treatment. There is a group of individuals who cannot take bisphosphonates orally at all. The alternative here is an intravenous injection. Therefore, there is a need for modifications of the existing therapeutic standards for osteoporosis. It is also necessary to emphasise the significance of intravenous medicines in the treatment of this disease.</p>\",\"PeriodicalId\":75702,\"journal\":{\"name\":\"Chirurgia narzadow ruchu i ortopedia polska\",\"volume\":\"76 4\",\"pages\":\"225-31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chirurgia narzadow ruchu i ortopedia polska\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chirurgia narzadow ruchu i ortopedia polska","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

口服双膦酸盐目前被认为是治疗骨质疏松症和预防老年性骨折的首选药物。然而,尽管有这些优点,这些药物也不是没有局限性的。最重要的是给药方式复杂,要求患者保持直立姿势并在饭前服药。这可能会使其他慢性药物(如甲状腺激素)的管理更加困难。治疗的并发症包括消化不良和胃肠道疾病。大约48%每周服用一次双膦酸盐的人在治疗开始后一年内退出治疗。有一群人根本不能口服双膦酸盐。另一种方法是静脉注射。因此,有必要修改现有的骨质疏松症治疗标准。同样有必要强调静脉注射药物在治疗这种疾病中的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Place of bisphosphonates in the primary andsecondary prophylaxis of osteoporotic fractures: the role of parenteral therapy--proposal to modify the standards of treatment].

Oral bisphosphonates are currently known as medicines of a first choice in the treatment of osteoporosis and in preventing age-related fractures. However, despite their advantages, these medicines are not free of limitations. The most significant one is a complicated way of tablet administration, requiring from patients to remain upright position and to take a tablet before a meal. This may make the administration of other, chronic medicines, such as thyroid hormones, more difficult. Complications of the therapy include dyspepsia and gastrointestinal disorders. Approximately 48% of individuals taking bisphosphonates once a week resign from therapy within one year from the beginning of the treatment. There is a group of individuals who cannot take bisphosphonates orally at all. The alternative here is an intravenous injection. Therefore, there is a need for modifications of the existing therapeutic standards for osteoporosis. It is also necessary to emphasise the significance of intravenous medicines in the treatment of this disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信